Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.73 |
| ▸ | RAB9A | P51151 | 6/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | KCNK3 | O14649 | 6/20 | 0.46 |
| ▸ | KCNK9 | Q9NPC2 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | TEK | Q02763 | 1/20 | 0.42 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1430465 | 0.85 | NPC1 (0.74) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL9587009 | 0.85 | NPC1 (1.00) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL4773388 | 0.84 | ALDH1A1 (0.78) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL19807597 | 0.82 | RAB9A (0.63) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL22001460 | 0.82 | NPC1 (0.74) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL21360469 | 0.82 | ALDH1A1 (1.00) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL18952253 | 0.81 | ALDH1A1 (0.73) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL29614093 | 0.81 | RAB9A (0.68) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL13599909 | 0.80 | NR1I3 (0.53) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL20587790 | 0.79 | ALDH1A1 (0.49) | NPC1RAB9AALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025082731-A1 | INTRANASAL FORMULATIONS FOR TREATING OBSTRUCTIVE SLEEP APNEA | MOSANNA THERAPEUTICS AG (CH) | 2025-04-24 | — | — | WO | disclosed |
| EP-3487856-B1 | SUBSTITUTED DIAZAHETERO-BICYCLIC COMPOUNDS AND THEIR USE | BAYER AG (DE) | 2025-01-22 | — | — | EP | disclosed |
| US-11208422-B2 | Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-12-28 | — | — | US | disclosed |
| US-20210024545-A1 | SUBSTITUTED DIAZAHETERO-BICYCLIC COMPOUNDS AND THEIR USE | BAYER AKTIENGESELLSCHAFT (DE) | 2021-01-28 | — | — | US | disclosed |
| US-10759794-B2 | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-09-01 | — | — | US | disclosed |
| EP-3386979-B1 | 2-PHENYL-3-(PIPERAZINOMETHYL)IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS BLOCKERS OF THE TASK-1 AND TASK-2 CHANNELS FOR TREATING SLEEP-RELATED BREATHING DISORDERS | Bayer Pharma AG (DE) | 2020-07-29 | — | — | EP | disclosed |
| EP-3386979-B1 | 2-PHENYL-3-(PIPERAZINOMETHYL)IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS BLOCKERS OF THE TASK-1 AND TASK-2 CHANNELS FOR TREATING SLEEP-RELATED BREATHING DISORDERS | Bayer Pharma AG (DE) | 2020-07-29 | — | — | EP | disclosed |
| US-20200140461-A1 | SUBSTITUTED BRIDGED DIAZEPANE DERIVATIVES AND USE THEREOF AS TASK-1 AND TASK-3 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-07 | — | — | US | disclosed |
| US-10414765-B2 | Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-09-17 | — | — | US | disclosed |
| EP-3386993-A1 | SUBSTITUTED PERHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND THE USE OF SAME | Bayer Pharma Aktiengesellschaft (DE) | 2018-10-17 | — | — | EP | disclosed |
| WO-2018015196-A1 | SUBSTITUTED DIAZAHETERO-BICYCLIC COMPOUNDS AND THEIR USE | BAYER AKTIENGESELLSCHAFT (DE) | 2018-01-25 | — | — | WO | disclosed |
| WO-2017097671-A1 | SUBSTITUTED PERHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND THE USE OF SAME | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017097792-A1 | 2-PHENYL-3-(PIPERAZINOMETHYL)IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS BLOCKERS OF TASK-1 AND TASK-2 CHANNELS, FOR THE TREATMENT OF SLEEP-RELATED BREATHING DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208422-B2 | Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors | BET1, HRH1, GRIN1 | NPC1 1804/4885RAB9A 4077/4885ALDH1A1 1483/4885 |
| US-20210024545-A1 | SUBSTITUTED DIAZAHETERO-BICYCLIC COMPOUNDS AND THEIR USE | HYOU1, DDAH1, VDAC3 | NPC1 813/4885RAB9A 4593/4885ALDH1A1 1341/4885 |
| US-20200140461-A1 | SUBSTITUTED BRIDGED DIAZEPANE DERIVATIVES AND USE THEREOF AS TASK-1 AND TASK-3 INHIBITORS | GRIN1, BET1, HRH1 | NPC1 1747/4885RAB9A 4140/4885ALDH1A1 1542/4885 |
| US-10414765-B2 | Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same | PAH, EGLN3, HYOU1 | NPC1 388/4885RAB9A 4337/4885ALDH1A1 796/4885 |
| US-10759794-B2 | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders | TRPV2, CACNA1G, KCNJ2 | NPC1 813/4885RAB9A 4129/4885ALDH1A1 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.